⭐ We recently spoke with @LorenzaRimassa of @HUNIMED on some of the key findings from the HIMALAYA and SIERRA trials in #hepatocellular carcinoma, including the long-term survival benefit observed with the STRIDE regimen: buff.ly/9iN7JDw

The FDA 🇺🇸 approved daraxonrasib, a first-in-class RAS inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received prior systemic therapy or cannot receive multiagent treatment. Taken daily, the drug targets RAS proteins that drive tumor growth. ✅️ The approval, issued ahead of schedule, provides a new treatment option for a cancer with limited therapies and poor outcomes. #PancreaticCancer buff.ly/5r4Q5Fb @CathyEngMD @BenWestphalen @graokane @NiuSanford @AndresC27622123 @GillSharlene @pashtoonkasi @DrVilmaPBarcia @Erman_Akkus @GIMedOnc @UOzkerim @MarioBalsaMD @p_ciracimd @DraMartinezLago @DaisukeKotani @Aiims1742 @ARosen380 @realbowtiedoc @KoheiShitara @MarioBalsaMD @realbowtiedoc @p_ciracimd @c_eng1 @sharlenegill @alicat380 @erman_akkus__ @ninan1230 @shitarakohei

The first map of acquired resistance to the tri-complex RAS(ON) inhibitor daraxonrasib in PDAC published today in @NatureMedicine nature.com/articles/s41591-0… The biology converges on KRAS amplification, MAPK reactivation, PI3K signaling, MYC and cell-state plasticity (partial EMT), providing a strong rationale for mechanism-based combination strategies to achieve deeper and more durable responses. Outstanding work by Ida Aronchik, Sumit Kar, Kevin Lin, Andy Aguirre, Mallika Singh and the entire multidisciplinary team. Excited to see where the field goes next. 💜💜 #KRAS #RAS #PancreaticCancer #sPARKlab #GRIT @RevMedicines @MSKCancerCenter @MSK_DeptOfMed @CpcrMsk @OncoAlert @oncodaily @OncBrothers @PanCAN @letswinpc @NatPancFdn @Pankind_Aus @KRASKickers

I am happy to share our first comprehensive report of the DREAM study outcome just published in the journal JAMA! 🩺 Historically, lung transplantation has not been offered to patients with advanced lung cancer due to concerns over poor oncological outcomes. Our prospective registry study challenges this paradigm for a highly selected group of patients. 🫁 I am incredibly grateful for the entire DREAM team, including @AnkitBharatMD, who worked tirelessly to care for this challenging group of patients while pushing the frontline of medicine forward. 🙏 Here are the key takeaways from our newly published research: 🔍 The Study Design Participants: We evaluated 98 adults with medically refractory, “lung-limited”, stage IV non-small cell lung cancer (NSCLC) experiencing respiratory failure. The Cohorts: 17 patients underwent lung transplantation using a dissemination-minimizing technique, while 81 eligible patients received standard medical management alone due to nonbiologic barriers. We also compared outcomes against 306 adults without cancer who underwent lung transplants. 📈 Promising Survival Outcomes 100% vs 40.8%: The estimated 1-year overall survival was 100% in the lung transplant group compared to just 40.8% for those who received medical management alone, a striking absolute difference of 59.2 percentage points! 📊 Excellent Post-Transplant Success: The 1-year posttransplant survival for stage IV NSCLC patients (100%) was highly favorable, even when compared to transplant recipients without cancer (88.1%). 💡 What This Means For carefully selected patients with medically refractory, lung-limited, stage IV NSCLC, lung transplantation can offer exceptionally favorable early survival compared to traditional medical management alone. While longer-term follow-up and quality-of-life assessments are still needed, these findings open a crucial new door for advanced lung cancer care. 🚪 🔗 Read the full paper here: jamanetwork.com/journals/jam… #LungCancer #LungTransplant @LurieCancer @NUFeinbergMed @NM_Lung @IASLC @LUNGevity @TheCancerLetter @OncoAlert @oncodaily @JAMAOnc @ASCO @myESMO @ISHLT @ttsorg @TheJHLT @amjtransplant @UNOSNews @SWOG @SupportingSWOG @WarOnCancer @EGFRResisters @ALKPositiveinc @targetcancer @OncodailyLung @ACSNews